Hereditary Parkinson s Disease Natural History Protocol
Parkinson Disease 6, Early-Onset · Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human · Parkinson Disease Autosomal Recessive, Early Onset · Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1
What this study involves
The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.
- Study type
- Observational
- Phase
- Not applicable / not listed
- Age range
- 18 years - 80 years
- Sex eligible
- All sexes
- Healthy volunteers
- Not accepted
- Participants
- 31 Actual
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
Background:
\- Parkinson s disease is a disease of the nervous system that affects movement. People usually get it in their 70s or 80s. Early onset Parkinson s disease (EOPD) begins before the age of 50. Researchers think EOPD may be caused by a mutation in a gene. They want to study the genetic causes so they can find therapies for this disease.
Objective:
\- To better understand the genetic causes of EOPD.
Eligibility:
- Adults ages 18 80 with a history of EOPD. Their family members, who do not have Parkinson s disease, can join as controls.
- Healthy volunteers ages 18 80.
Design:
- Participants with EOPD and their relatives will be screened with a review of medical records. Healthy volunteers will have medical history, physical exam, and blood drawn.
- Relatives may send blood samples to NIH to test for mutations in genes that are linked to Parkinson s disease. They may have a physical exam.
- Participants may be asked to return to clinic for another visit that can last up to 2 hours.
- During this visit, participants will have blood taken from a vein in the arm via a needle stick.
- Participants may give a sample of their skin. The skin on the arm or leg will be numbed and a small skin punch biopsy will be taken with a special needle.
- Some cells from the blood or skin sample may be grown in a lab to establish cell lines. The cells may also potentially be genetically modified to make stem cells.
- Researchers may perform genetic analysis on the samples to compare them to EOPD patient samples.
Read the full description
The majority of subjects with the degenerative Parkinson's Disease (PD) present in the 7th and 8th decades of life. In contrast, this neurologic disease can present within the first 5 decades of life. This early onset presentation is more likely to have a direct genetic cause relative to the etiology of the degenerative form of the disease. Our understanding of the genetic causes of early onset Parkinson's Disease (EOPD) may help us find therapies for both the genetic and degenerative illnesses. Data from our laboratory and others show that genetic mutations associated with EOPD, disrupt cellular stress-response programs. These perturbations, in turn, impair cell-repair process, which is hypothesized to increase susceptibility to dopaminergic neuron degeneration linked to EOPD and degenerative PD. At the same time, patients with EOPD have a variable age of onset (spanning from 8 years to 41 years in the subjects in our cohort) and disease penetrance (severity of symptoms). The hypothesis we propose to test is whether the number and allele distributions of EOPD susceptibility gene mutations account for the variable age of onset and disease penetrance. This hypothesis will be tested in this natural history protocol by genotyping subjects with EOPD to define their genetic defects and to explore the cellular reparative function in these individuals using peripheral blood cells, skin biopsy derived fibroblasts and induced pluripotential stems cells derived from these subjects. In parallel, the phenotype of these subjects will be evaluated by the NINDS Parkinson's Clinic. Together, these data should advance our insight into the genotype-phenotype in EOPD pathophysiology.
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
- INCLUSION CRITERIA
Parkinson's Subjects
\- Age 18 years to 80 years old with a history of early onset Parkinson's disease or Parkinsonism (Presentation within the first five decades of life).
Healthy Control Subjects
\- Age 18 years to 80 years old with no history or family history of Parkinson's disease or Parkinsonism.
Family Member Control Subjects
-Family members, of enrolled EOPD subjects, who themselves do not have Parkinson's disease or Parkinsonism can be enrolled as controls on this study.
All Subjects
- Willingness and legal ability to give and sign informed study consent
- Willingness to have blood or tissue samples studied, and potentially stored for future research
EXCLUSION CRITERIA
All Subjects
- Subjects who are unable or unwilling to sign an informed consent
- Subjects with genetic defects associated with diseases including other neurologic syndromes.
- Pregnancy
Study population
Subjects that develop symptoms of Parkinson Disease within the first 5 decades of life would be enrolled onto this protocol. Additionally, subjects previously enrolled on protocol 12-H-0084 may also be enrolled on this protocol. Age (+/- 5 yrs) and gender matched healthy volunteers will be recruited as controls for this protocol. Controls will be recruited via web advertisements. An email advertisement will also be sent out via the NIH LISTSERV to aid in the recruitment of healthy volunteers. A list of healthy volunteers may also be requested from the NIH Office of Patient Recruitment. Family member controls without clinical evidence of Parkinsonism may be recruited as controls for index research subjects.
Understand screeningTreatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Not reported
- Masking
- Not reported
Family Member Control Subjects
Family members, of enrolled EOPD subjects, who themselves do not have Parkinson disease or Parkinsonism can be enrolled as controls on this study.
Healthy Control Subjects
Age 18 years to 80 years old with no history or family history of Parkinson disease or Parkinsonism.
Parkinson Subjects
Age 18 years to 80 years old with a history of early onset Parkinson disease or Parkinsonism (Presentation within the first five decades of life).
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
The primary objective of this study is to genetically define the combination of autosomal recessive genetic defects linked to EOPD and characterize their composite molecular and physiologic effect on cellular homeostasis and response to dopamine...
Time frame: 5 years
genetically define the combination of autosomal recessive genetic defects linked to EOPD and characterize their composite molecular and physiologic effect on cellular homeostasis and response to dopaminergic stressors.
Secondary measures
The secondary objective is to evaluate whether these composite of these genetic defects and their effects on cellular quality control correlate to age of onset and disease penetrance in EOPD subjects.
Time frame: 5 years
The secondary objective is to evaluate whether these composite of these genetic defects and their effects on cellular quality control correlate to age of onset and disease penetrance in EOPD subjects.
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (1)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
1 locations
National Institutes of Health Clinical CenterBethesda, Maryland, United StatesStatus unknown
Study team and timeline
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- Jul 8, 2015 Actual
- Primary completion
- Apr 7, 2016 Actual
- Study completion
- Aug 15, 2017 Actual
- First posted
- Jul 29, 2015 Estimated
- Last updated
- Nov 10, 2026 Actual
Official study contacts
No central contact is listed. Check the locations and the official record.
Official study title
Hereditary Parkinson Disease Natural History Protocol
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 11, 2026 · Last registry update: Nov 10, 2026